Nearly 50% of the Total Revenue in the Benign Prostatic Hyperplasia Laser Therapy Market is Projected to Arrive from Drug Classes by 2031 End

The market study done by Fact.MR gives exclusive information about how the market will grow. The study identifies crucial trends that are determining the growth of Benign Prostatic Hyperplasia Laser Therapy market. This newly published report sheds light on vital dynamics, such as the drivers, restraints, and opportunities for key market players as well as emerging players associated with the production and supply. The latest report by Fact.MR provides detailed Market Analysis of Benign Prostatic Hyperplasia Laser Therapy

The report offers actionable and valuable market insights of Benign Prostatic Hyperplasia Laser Therapy. The latest report by Fact.MR provides details on the present scenario of the market across various regions along with the historic data and forecast of the market. The report also includes information on the sales and demand of Benign Prostatic Hyperplasia Laser Therapy Market across various industries and regions.

To remain ‘ahead’ of your competitors, request for a sample –  https://www.factmr.com/connectus/sample?flag=S&rep_id=4412

This newly published and insightful report sheds light on Market Insights of Benign Prostatic Hyperplasia Laser Therapy, key dynamics, their impact on the overall value chain from suppliers to end-users and Growth of Benign Prostatic Hyperplasia Laser Therapy Market.

An exhaustive study published by Fact.MR finds that, transurethral resection of prostate (TURP) surgery is expected to contribute around 30% of market share by 2027, as it is proving highly-effective over drugs for the treatment of benign prostatic hyperplasia (BPH). High success rate of the TURP surgery is encouraging market players to further explore advanced technologies and increase surgical precision. On account of technological leaps, robotic surgery and laser therapy are the most recent breakthroughs in the benign prostatic hyperplasia treatment market, which are being fast-adopted by medical professionals to relieve the symptoms of BPH.

opportunity assessment in benign prostatic hyperplasia treatment market by end user

However, these high-end therapeutics are currently not under the ambit of insurance, resulting in high out-of-pocket spending for patients. To sum it all, the study expects moderate growth of the benign prostatic hyperplasia treatment market during the forecast period (2020-2027).

Need more information about Report Methodology? Click here-  https://www.factmr.com/connectus/sample?flag=RM&rep_id=4412

Benign Prostatic Hyperplasia Market – Assessment of Key Segments

Authors of this comprehensive study have classified the BPH treatment market into key segments for an in-depth study of the market. Categorisation of the benign prostatic hyperplasia treatment market is based on treatment type, end user, and region. This detailed study also offers information about the incremental opportunities present in the benign prostatic hyperplasia treatment market during the forecast period. Key segments considered while studying the benign prostatic hyperplasia treatment market include:

Treatment Type
  • Drug Classes
    • Alpha Blockers
    • 5-Alpha-reductase Inhibitors (5-ARIs)
    • Phosphodiesterase-5 Enzyme Inhibitors
    • Others
  • Minimally-invasive Surgeries
    • Transurethral Resection of the Prostate (TURP)
    • Transurethral Incision of the Prostate (TUIP)
    • Robotic Surgeries
    • Transurethral Microwave Thermotherapy (TUMT)
    • Prostatic Urethral Lift
    • Others
  • Laser Therapy
  • Others
End User
  • Hospitals
  • Ambulatory Surgical Centres
  • Specialty Clinics
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Full Access of this Exclusive Report is Available at-  https://www.factmr.com/checkout/4412

Key Highlights of Benign Prostatic Hyperplasia Treatment Market Study

  • Hospitals will remain key treatment centres, with over 40% revenue contribution to the BPH treatment market during 2020-2027. However, expensiveness of TURP surgeries, lengthy procedures, and long stays in hospitals are diverting patients’ inclination towards specialty clinics.
  • Manufacturers continue to extend efforts towards enhancing product efficacy, which is strengthening the pipeline for BPH treatment with numerous inhibitors and immunotherapies in phase II and phase III trials. This signifies a sustainable supply of branded therapeutics during the forecast period.
  • The U.S. is projected to account for around 25% of the global BPH treatment market share during 2020-2027, as regional manufacturers gain the early-slice of technology to foster innovation. However, India is projected to grow at the highest rate in the benign prostatic hyperplasia treatment market, on account of relatively low BPH treatment costs that attract a large number of medical tourists.
  • Loss of patent exclusivity of branded drugs is increasing the availability of generic drugs, which prevents the benign prostatic hyperplasia treatment market from reaching its true revenue potential.

A senior consultant at Fact.MR opines,“Manufacturers can target expansions in India and China, as relatively low setup and labour costs would result in reduced price of products, and, in turn, improve the adoption rate of otherwise expensive therapeutics. Also, a large geriatric population in Japan and high prevalence of BPH among men over 50 years are likely to increase market opportunities in this country.”

Rise in Medical Tourism Catapulting Indian Benign Prostatic Hyperplasia Treatment Market

According to the Fact.MR study, the typical cost of transurethral resection of the prostate (TURP) in the U.S. ranges from US$ 8,000 to US$ 12,000, while cost of the same surgery in India is significantly lower (around US$ 1,500 to US$ 6,000). Cost benefits of TURP surgery in India are despite the use of cutting-edge technology and diagnostic equipment by surgeons for offering better patient outcomes.

This is creating a novel revenue stream for the benign prostatic hyperplasia treatment market through medical tourism, especially driven from patients from Western countries such as the U.S. and the U.K. Also, hospitals—both, private and public—are free from long waitlists, and India has also relaxed visa policies, which further turns the country favourable for medical tourism.

A similar trend is being witnessed in the BPH treatment market in Japan. High technological advancements are complementing developmental efforts of manufacturers, such as Olympus Corporation, Astellas Pharma, Inc., Asahi Kasei Corporation, operating in Japan. On the back of medical tourism strengthening demand and intense R&D efforts ensuring long-term supply, the benign prostatic hyperplasia treatment market in Asia Pacific is witnessing an accelerated pace, projected to expand at a CAGR of 7.3% during the forecast period.

Read More Trending Reports of Fact.MR- https://www.biospace.com/article/demand-for-tricuspid-valve-repair-rising-as-congenital-and-rheumatoid-heart-disease-cases-increase-fact-mr/

Key Question answered in the survey of Benign Prostatic Hyperplasia Laser Therapy market report:

  • Sales and Demand of Benign Prostatic Hyperplasia Laser Therapy
  • Growth of Benign Prostatic Hyperplasia Laser Therapy Market
  • Market Analysis of Benign Prostatic Hyperplasia Laser Therapy
  • Market Insights of Benign Prostatic Hyperplasia Laser Therapy
  • Key Drivers Impacting the Benign Prostatic Hyperplasia Laser Therapy market
  • Which are the Key drivers impacted by Benign Prostatic Hyperplasia Laser Therapy market
  • Restraints Shaping Market Growth
  • Market Survey of Benign Prostatic Hyperplasia Laser Therapy

More Valuable Insights on Benign Prostatic Hyperplasia Laser Therapy Market

Fact.MR, in its new report, offers an unbiased Market Analysis of Benign Prostatic Hyperplasia Laser Therapy, Sales and Demand of Benign Prostatic Hyperplasia Laser Therapy, analyzing forecast statistics through 2019 and beyond. The study reveals growth projections on the basis of various criteria.

Explore Fact.MR’s Comprehensive Coverage on Healthcare Domain:

Fluoro Enzymatic Assays Market – Global Industry Analysis and Opportunity Assessment 2021 – 2031

Shower Chairs Market – Global Industry Analysis and Opportunity Assessment 2021 – 2031

Infrared Thermometer Market – Global Industry Analysis and Opportunity Assessment 2021 – 2031

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:

11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Email: sales@factmr.com

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *

© 2022 The Tribune City - Theme by WPEnjoy · Powered by WordPress